This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           June 03, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Gyn Onc at ASCO 2015
David O’Malley, MD, from The Ohio State University in Columbus, OH, discusses two abstracts on carboplatin combination therapies for advanced stage or recurrent endometrial cancer: The GOG-86P study and the European MITO END-2 trial.
WATCH
Angeles Alvarez-Secord, MD, from Duke University Medical Center in Durham, NC, describes the findings from two ovarian cancer abstracts: A retrospective analysis of candidate predictive tumor biomarkers in the GOG-0218 trial and the Phase III PENELOPE trial evaluating the addition of pertuzumab.
WATCH
Deanna Teoh, MD, from the University of Minnesota in Minneapolis, MN, talks about the results of a Phase II study on AZD1775, a Wee1 inhibitor, for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.
WATCH
Ritu Salani, MD, MBA, from The Ohio State University, discusses findings from two abstracts on drugs being studied for the treatment of ovarian cancer: A Phase I NRG/GOG study on veliparib and the Phase II ARIEL2 trial on rucaparib.
WATCH
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
  




CERVICAL CANCER


Public comment on draft research plan: Screening for cervical cancer
U.S. Preventive Services Task Force
The U.S. Preventive Services Task Force posted on May 28 a draft research plan on screening for cervical cancer. The draft research plan is available for review and public comment from May 28 through June 24, 2015. To review the draft research plan and submit comments, click here.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Ovarian cancer competition accelerates with new drug data
Bloomberg Business
In a midstage study of 204 patients, rucaparib shrunk tumors in 32 of 39 ovarian cancer patients with BRCA mutations. Four women in that group had their tumors disappear, known as a complete response. The study data was released Saturday at the American Society of Clinical Oncology’s meeting in Chicago.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


Large ovarian cancer study reveals new clues on genetics of chemoresistance
Medical News Today
A large study of the genetic mechanisms of chemoresistance in high-grade serous ovarian carcinoma reveals new clues on why the deadliest and most common form of ovarian cancer so often returns after initially successful chemotherapy.The new study is published in the journal Nature.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MORCELLATION


FBI investigating medical device that spread cancer in women
CBS News
The FBI reportedly is investigating a medical device that was withdrawn from the market last year after it was found to spread cancer in women. The Wall Street Journal reports investigators are looking into what Johnson & Johnson, the largest manufacturer of the device, knew about the problems. The device, known as a laparoscopic power morcellator, was used by surgeons during certain minimally-invasive hysterectomy procedures or to remove uterine fibroids.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Advertisement
Register today!

Join ECG in Chicago on May 29th for an interactive symposium on BRCA Related Ovarian Cancer, Chaired by Thomas J. Herzog, MD.

Register today

Advertisement
Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.


HEALTH POLICY


Federal investigators fault Medicare's reliance on doctors for pay standards
The New York Times
The government relies too heavily on advice from the American Medical Association in deciding how much to pay doctors under Medicare, and the decisions may be biased because the doctors have potential conflicts of interest, federal investigators say in a new report. This reliance on the association, combined with flaws in data collected by the influential doctors’ group, “could result in inaccurate Medicare payment rates,” the investigators said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




OBESITY


ASCO Obesity Initiative: How does obesity affect cancer outcomes?
Cancer Network
About 2 years ago in recognition of the growing rates of obesity in the United States and beyond, as well as the emerging evidence that obesity and related factors like inactivity and poor dietary quality are linked not only to the risk of developing cancer but also to the risk of recurrence and overall mortality in individuals with cancer, ASCO launched the first Energy Balance Work Group that was designed to look at the evidence linking obesity and related factors to cancers and to start to develop some priorities around this topic.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Procedure eliminates need for second breast cancer surgery
MedPage Today
Taking more tissue during partial mastectomy reduces the risk of later reoperation, without affecting cosmetic outcomes of breast cancer surgery, a researcher said. In a randomized trial, so-called cavity shaving reduced the rate of positive margins and re-excision by about half, according to Anees Chagpar, MD, of Yale Cancer Center. But patients did not perceive a cosmetic difference in the results, Chagpar reported at the annual meeting of the American Society of Clinical Oncology and simultaneously in the New England Journal of Medicine.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

May 27, 2015
May 20, 2015
May 13, 2015
May 6, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063